Sequoia Financial Advisors LLC Has $2.15 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Sequoia Financial Advisors LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 27,964 shares of the biopharmaceutical company’s stock after selling 1,983 shares during the period. Sequoia Financial Advisors LLC’s holdings in Gilead Sciences were worth $2,152,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Laurel Wealth Advisors LLC increased its position in Gilead Sciences by 225.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 225 shares during the period. Bainco International Investors acquired a new position in Gilead Sciences in the 1st quarter valued at approximately $29,000. Global Wealth Management Investment Advisory Inc. increased its position in Gilead Sciences by 66.5% in the 2nd quarter. Global Wealth Management Investment Advisory Inc. now owns 388 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 155 shares during the period. RMR Wealth Builders acquired a new position in Gilead Sciences in the 2nd quarter valued at approximately $30,000. Finally, Pacific Center for Financial Services increased its position in Gilead Sciences by 130.5% in the 2nd quarter. Pacific Center for Financial Services now owns 484 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 274 shares during the period. Hedge funds and other institutional investors own 77.87% of the company’s stock.

Several equities analysts have issued reports on GILD shares. Cantor Fitzgerald decreased their price target on shares of Gilead Sciences from $86.00 to $84.00 and set an “overweight” rating for the company in a research report on Wednesday, August 19th. ValuEngine raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Monday, August 3rd. DZ Bank reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Monday, June 15th. BidaskClub lowered shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 24th. Finally, Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $69.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 19th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $78.78.

Shares of Gilead Sciences stock traded down $0.04 during trading hours on Tuesday, reaching $66.30. The company’s stock had a trading volume of 483,327 shares, compared to its average volume of 15,585,797. Gilead Sciences, Inc. has a one year low of $60.89 and a one year high of $85.97. The company has a market capitalization of $83.17 billion, a P/E ratio of -277.82, a P/E/G ratio of 0.67 and a beta of 0.56. The stock’s fifty day simple moving average is $67.89 and its two-hundred day simple moving average is $73.89. The company has a debt-to-equity ratio of 1.22, a quick ratio of 2.23 and a current ratio of 2.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.46). Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.24 billion. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.95 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.10%. The ex-dividend date of this dividend is Monday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 44.30%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Learning About the VIX – Volatility Index

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.